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Outcomes following treatment of in-stent restenosis
DEB DES Total p
MACE 25 (26%) 21 (24%) 46 (25%) 0.80
Death 15 (16%) 6 (7%) 21 (12%) 0.06
Non-fatal MI 8 (9%) 10 (13%) 18 (11%) 0.43
TLR 7 (8%) 10 (13%) 17 (10%) 0.26
Restenosis ‡
50%
10 (11%) 10 (13%) 20 (12%) 0.72
Thrombosis 1 (1%) 1 (1%) 2 (1%) 0.93
Stroke/TIA 1 (1%) 1 (1%) 2 (1%) 0.96
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Background: few data are available about safety of second generation drug eluting
stents in an all-comer ST elevation myocardial infarction (STEMI) population. We
sough to investigate the predictors and clinical implications of 1-year stent thrombosis
(ST) in patients with STEMI, included the EXAMINATION trial.
Methods: TheEXAMINATION trial is an all-comer prospective, randomized1:1 controlled
trial, testing everolimus-eluting stent (EES) vs. cobalt chromium bare metal stent (BMS) in
STEMI patients. It included 1498 patients, randomized to EES (n¼751) or BMS (n¼747).
Results: At 1-year, deﬁnite/probable stent thrombosis, deﬁned according to ARC
criteria, occurred in 26 patients (1.73%), including 18 deﬁnite and 8 probable events.
The incidence of ST was lower in patients treated with EES than in those treated with
BMS (HR 0.16, 95% CI 0.03 – 0.29, p¼0.017). Patients with ST have higher 1-year
rates of cardiac death (30.8% vs. 2.5%, p<0.001), myocardial infarction (30.8% vs.
0.5%, p<0.001) and target vessel revascularization (65.4% vs. 4.2%, p<0.001)
compared with those without. Independent predictors of 1-year deﬁnite/probable ST
were BMS implantation at the index procedure (HR 3.41,95% CI 1.35–8.60), ST
segment resolution of at least 70% in the EKG post-PCI (HR 0.30,95% CI 0.13–0.70)
and Killip class on admission (HR 2.57,95% CI 1.70–3.90).
Conclusions: ST had low frequency in the ﬁrst year after implantation of EES/BMS in
STEMIpatients,but it is associatedwithadverseevents.BMSimplantation, lackofST-segment
resolution and high Killip class on admission were independent predictors of 1-year ST.
TCT-448
Long-Term Clinical Results Of SeQuent Please Paclitaxel-Coated Balloon
Angioplasty For The Treatment Of In-Stent Restenosis
Javier Benezet1, Ignacio Sanchez-Perez1, Fernando Lozano1, Felipe Higuera1,
Natalia Pinilla1, Yasser Hessein1
1Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
Background: Paclitaxel-coated balloons (PCB) have been proven to be effective for the
treatment of coronary in-stent restenosis (ISR) after bare-metal stent (BMS) or drug-eluting
stent (DES) implantation. This study aims to evaluate the long-term safety and efﬁcacy of
the second-generation SeQuent Please PCB in coronary ISR in routine real-world practice.
Methods: BetweenMay 2009 and April 2011, all consecutive patients with ISR lesions
treated with the SeQuent Please PCB at our institution were prospectively included.
Patients were followed up for 24 months by clinical observation. The primary endpoint
was the clinically driven target lesion revascularization (TLR) rate at 24 months. The
secondary endpoint was the rate of major adverse cardiac events (MACE: deﬁned as
a composite of cardiac death, myocardial infarction, and TLR) at 24 months.
Results: 48 patients with 52 ISR lesions (30 BMS, 22 DES) were included. Mean age
was 66.212.3 years. 75 % were male and 50 % were diabetics. The majority of
patients presented with stable angina (63.5%). The target lesion was mainly located in
the right coronary artery (46.1%) and the left anterior descending coronary artery
(42.3%). The mean reference vessel diameter was 3.00.5 mm and the mean target
lesion length was 21.46.8 mm.Procedural success was 100 %. Coronary dissection
occurred in 1 patient (1.9 %), requiring additional stent implantation. Follow-up rate
was 94.2 %. The TLR rate was 5.8 % after 24 months. Cumulative MACE at 24
months was 9.6 %, with 1.9 % cardiac death and 1.9 % myocardial infarction. No
vessel thrombosis was documented. The TLR rate did not differ for PCB angioplasty
for BMS-ISR compared with DES-ISR (3.3% vs. 9.1%, p¼0.38). Baseline lesion
characteristics and procedural data did not differ except for a longer lesion length for
BMS-ISR compared with DES-ISR (25.4 5.1 mm vs. 19.76.9 mm, p¼0.008).B138 JACC Vol 62/18/Suppl B j October 27–November 1, 20Conclusions: Treatment of coronary ISR with the second-generation SeQuent Please
PCB provides good clinical outcomes demonstrated by the low TLR rate and low
MACE rates at long-term follow-up.
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Background: The optimal treatment strategy for coronary in-stent restenosis (ISR) is
unclear. Drug-eluting balloons (DEB) offer an alternative to drug-eluting stents (DES)
by avoiding risks of stent thrombosis, and by lowering the risks of restenosis asso-
ciated with standard balloon angioplasty and bare-metal stents. The objectives were to
compare clinical outcomes of DEB versus second-generation DES for the treatment of
ISR. The hypothesis was that DEB and DES would provide similar outcomes.
Methods: FromDecember 2009 toNovember 2012, 102 coronary ISRwere treatedwith
a paclitaxel-eluting balloon in all-comer patients in a Canadian tertiary center. The
comparator group consisted of a random sample of 100 patients with ISR treated with
a second-generation DES in the same time period. Data was collected frommedical ﬁles
and telephone interviews. Mean follow-up was 169 months (222 patient-years).
Baseline characteristics were similar between both groups (mean age: 6511 [p¼0.91];
28%women [p¼0.69]).Diabeteswas present in 45%of patients (p¼0.79). Indication for
revascularization was non-ST-elevation acute coronary syndrome in 71% of cases in the
DEB group as compared to 73% in the DES group (p¼0.37).
Results: The composite clinical outcome of MACE (death from any cause, non-fatal
myocardial infarction, or clinically-driven target-lesion revascularization) occurred in
26% of patients in the DEB group, compared to 24% in the DES group (p¼0.80).
Freedom from MACE was similar between both groups after adjustment for con-
founding factors. Secondary outcomes are shown in the Table.
Conclusions: DEB appears as a safe and effective treatment for ISR as compared to
second-generation DES. Our data suggest that clinical outcomes following revasculari-
zationwith bothdevices are similar.Long-termclinical outcomes following ISR treatment
with a DEB compared to second-generation DES remain to be prospectively studied.TCT-450
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Background: Success of in-stent restenosis (ISR) treatment depends on angiographic
lesion characteristics and co-morbidities. The optimal treatment option for ISR
between drug-eluting balloons (DEB) or drug-eluting stents (DES) is not well known.
The objectives were to assess risk factors for adverse outcomes following ISR treat-
ment, and to evaluate the use of DEB in this setting.
Methods: Multivariate binary logistic regression was performed to assess predictors
of treatment success following ISR treatment in a cohort including 102 patients treated
with paclitaxel-eluting balloons and 100 random patients treated with a second-
generation DES between December 2009 and November 2012 in a Canadian tertiary
center (mean follow-up: 169 months; mean age: 6511 years). The effect of using
a DEB was adjusted for angiographic and clinical confounders. Indication for
revascularization was non-ST-elevation acute coronary syndrome in 145 cases (72%).
Lesion localization was similar in both groups (p¼0.45): 4% left main, 33% LAD,
27% circumﬂex, and 37% RCA. ISR pattern was focal in 62% of patients in the DEB
group, compared to 46% in the DES group (p¼0.02).
Results: Compared to diffuse, proliferative or occlusive lesions, a focal ISR was
a protective factor against death (OR¼0.2; p¼0.01), and target-lesion revasculariza-
tion (TLR) (OR¼0.3; p¼0.04), but not against MACE (death, non-fatal myocardial
infarction [MI], and TLR) (p¼0.29), MI (p¼0.95), or 50% restenosis (p¼0.19).
DEB/DES length was associated with MACE (OR¼1.0; p¼0.03), and death
(OR¼0.9; p¼0.001), but not with TLR, MI, and 50% restenosis (p>0.05 each).
DEB/DES diameter was associated with none of these outcomes (p>0.05 each).
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